ReviewActa neurochirurgica2024
MR-guided laser interstitial thermal therapy in the treatment of brain tumors and epilepsy.
Review in Acta neurochirurgica, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Laser interstitial thermal therapy in pediatric neurosurgery: a prospective nationwide study on indications, safety, and early outcomes.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2026Article
- Laser Interstitial Thermal Therapy for High-Grade Gliomas: Current Evidence, Clinical Applications and Emerging Role of Artificial Intelligence.Journal of clinical medicine · 2026Review
- Single-center longitudinal experience with MRgLITT in pediatric neurosurgery: technical evolution, expanding indications, and advanced MRI-driven planning.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2026Article
- Biopsy with same-session MRI-guided laser interstitial thermal therapy versus biopsy alone in patients with primary unresectable glioblastoma: a multicentre randomised controlled trial.The Lancet regional health. Europe · 2026Article
- Review
- Review
- MR-Guided Laser Interstitial Thermal Therapy for Recurrent Glioblastoma: A Case Report With Novel Insights Into Histopathological Changes and Immunological Responses.Neuropathology and applied neurobiology · 2026Article
- Epilepsy in Patients with Cerebral Radiation Necrosis: A Scoping Review.Medicina (Kaunas, Lithuania) · 2026Article
- Laser interstitial thermal therapy for IDH wild-type recurrent glioblastoma: a Scandinavian two-center cohort study.Acta neurochirurgica · 2026Article
- Diagnostic imaging and emerging image-guided neurointervention in brain tumors: a narrative review.Frontiers in radiology · 2026Review
- Review
- Predictors of prolonged length of stay in patients undergoing laser interstitial thermal therapy for intracranial tumors.Journal of neuro-oncology · 2025Article
- Focused ultrasound in pediatric neurosurgery: a scoping review of opportunities and challenges.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2025Article
- Levetiracetam and valproic acid in glioma: antiseizure and potential antineoplastic effects.Future oncology (London, England) · 2025Review
- Blood-brain barrier disruption following MR-guided laser interstitial thermal therapy.Neuro-oncology advancesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
MR-guided Laser Interstitial Thermal Therapy (MRgLITT) is a minimally invasive neurosurgical technique increasingly used for the treatment of drug-resistant epilepsy and brain tumors. Utilizing near-infrared light energy delivery guided by real-time MRI thermometry, MRgLITT enables precise ablation of targeted brain tissues, resulting in limited corridor-related morbidity and expedited postoperative recovery. Since receiving CE marking in 2018, the adoption of MRgLITT has expanded to more than 40 neurosurgical centers across Europe. In epilepsy treatment, MRgLITT can be applied to various types of focal lesional epilepsy, including mesial temporal lobe epilepsy, hypothalamic hamartoma, focal cortical dysplasias, periventricular heterotopias, cavernous malformations, dysembryoplastic neuroepithelial tumors (DNET), low-grade gliomas, tuberous sclerosis, and in disconnective surgeries. In neuro-oncology, MRgLITT is used for treating newly diagnosed and recurrent primary brain tumors, brain metastases, and radiation necrosis. This comprehensive review presents an overview of the current evidence and technical considerations for the use of MRgLITT in treating various pathologies associated with drug-resistant epilepsy and brain tumors.
Indexed as
Identifiers
39167226What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.